Answers are grounded in this paper and cite their sources.
Review shows the importance of integrating biomarkers with histopathology and molecular testing for renal cell carcinoma.
A precise diagnosis integrating histopathology, IHC, and molecular testing is critical for guiding management, identifying hereditary syndromes, and implementing personalized tumor biology-based therapies. With evolving molecular diagnostic and circulating biomarkers, careful clinical integration is needed to optimize outcomes and treatment.
No takes yet. Share an insight, caveat, or question.
Orsatti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: